keyword
MENU ▼
Read by QxMD icon Read
search

Pet psma

keyword
https://www.readbyqxmd.com/read/28346248/68ga-psma-pet-ct-in-osteosarcoma-in-fibrous-dysplasia
#1
Arun Sasikumar, Ajith Joy, M R A Pillai, Tony M Alex, Geetha Narayanan
Fibrous dysplasia (FD) is a benign bone lesion with a rare but potential for malignant transformation. Neither Tc-MDP nor F-FDG PET/CT can differentiate between FD and areas of malignant transformation in FD. We described a case of osteosarcoma developing in FD with selective uptake of tracer in malignant transformation areas demonstrated on a Ga-PSMA PET/CT scan. Our case highlights the ability of Ga-PSMA PET/CT to map tumor neoangiogenesis in osteosarcoma arising in FD, which can have potential implications in prognostication, possibility of antiangiogenesis-based therapeutic options, and in response assessment following chemotherapy...
March 24, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28338640/metal-based-psma-radioligands
#2
REVIEW
Eleni Gourni, Gjermund Henriksen
Prostate cancer is one of the most common malignancies for which great progress has been made in identifying appropriate molecular targets that would enable efficient in vivo targeting for imaging and therapy. The type II integral membrane protein, prostate specific membrane antigen (PSMA) is overexpressed on prostate cancer cells in proportion to the stage and grade of the tumor progression, especially in androgen-independent, advanced and metastatic disease, rendering it a promising diagnostic and/or therapeutic target...
March 24, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28336288/incidental-malignancies-identified-during-staging-for-prostate-cancer-with-68-ga-psma-hbed-cc-pet-imaging
#3
Andre Joshi, Cheryl Nicholson, Handoo Rhee, Sonja Gustafson, Ken Miles, Ian Vela
The rapid uptake of 68Ga Prostate-Specific Membrane Antigen (PSMA) HBED-CC PET imaging for prostate cancer staging has led to concerns regarding its specificity, with uptake in both malignant and non-malignant tissues. We describe three separate malignancies identified on 68Ga PSMA HBED-CC PET imaging. The misnomer of "prostate specific membrane antigen" is demonstrated by this case and highlights the importance of continued investigation of the potential role for 68Ga PSMA HBED-CC PET in other malignancies...
March 20, 2017: Urology
https://www.readbyqxmd.com/read/28319497/vertebral-hemangioma-mimicking-bone-metastasis-in-68ga-psma-ligand-pet-ct
#4
Carlos Artigas, François-Xavier Otte, Marc Lemort, Roland van Velthoven, Patrick Flamen
Ga-PSMA PET/CT was performed in a 68-year-old man to evaluate recurrent prostate cancer due to elevated serum prostate-specific antigen level. Images showed a focal uptake in the prostatic gland, suggesting local relapse, and an intense uptake in the 12th thoracic vertebra, with no morphological abnormalities in CT slices. In order to confirm extraprostatic disease and before radiotherapy planning, a full-spine MRI was performed, resulting with the morphological pattern of a vertebral hemangioma. Hystological analysis confirmed the local relapse in the prostate...
March 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28319496/the-utility-of-68ga-psma-pet-ct-in-poorly-differentiated-metastatic-prostate-cancer
#5
Mehmet Onur Demirkol, Murat Can Kiremit, Omer Acar, Burcu Ucar, Yesim Saglican
We aimed to emphasize how useful PSMA PET/CT findings can be while trying to restage prostate cancer after radical prostatectomy in the presence of low prostate-specific antigen values. A 64-year-old man with pT3b N1 M0 Gleason 7 adenocarcinoma of the prostate presented 5 years postoperatively with a palpable axillary mass, whereas his prostate-specific antigen was 0.08 ng/mL. Conventional imaging studies and histopathologic findings of the axillary mass biopsy revealed inconclusive results. Ga-PSMA PET/CT demonstrated PSMA-positive metastatic lesions, the largest one being located in the right axilla...
March 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28317152/-68-ga-psma-pet-for-radiation-treatment-planning-in-prostate-cancer-recurrences-after-surgery-individualized-medicine-or-new-standard-in-salvage-treatment
#6
Gregor Habl, Katharina Sauter, Kilian Schiller, Sabrina Dewes, Tobias Maurer, Matthias Eiber, Stephanie E Combs
BACKGROUND: (68) Ga-PSMA-PET imaging is a novel promising diagnostic tool to locate early biochemical failure after radical prostatectomy (RP) in prostate cancer (PC) patients. Exact knowledge of the relapse location may result in changes of the therapy concept aside from changes to the TNM stage. To gain data for this approach, we evaluated PC patients receiving (68) Ga-PSMA-PET imaging before salvage radiotherapy (RT). METHODS AND MATERIALS: In this study, 100 patients with biochemical failure after RP± prior RT who underwent (68) Ga-PSMA PET/CT or PET/MRI were evaluated undergoing salvage RT in our department...
March 20, 2017: Prostate
https://www.readbyqxmd.com/read/28314971/-when-is-surgical-treatment-indicated-in-metastatic-prostate-cancer-and-what-is-the-scientific-rationale
#7
A Kretschmer, A Herlemann, C G Stief, C Gratzke
BACKGROUND: Recent improvements in imaging diagnostics has led to a rising incidence of oligometastatic prostate cancer and, most notably, an increasing incidence of nodal-only biochemical recurrences. In this clinical setting, systemic therapy is still the treatment of choice. However, there is increasing evidence for surgical approaches in this challenging clinical setting. AIM OF THE STUDY: In this comprehensive review article, current evidence regarding surgical approaches of primary nodal metastases, nodal-only biochemical recurrence following radical prostatectomy, and osseous metastatic prostate cancer will be discussed...
March 17, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28314292/-68-ga-psma-ligand-pet-ct-based-radiotherapy-for-lymph-node-relapse-of-prostate-cancer-after-primary-therapy-delays-initiation-of-systemic-therapy
#8
Christoph Henkenberens, Christoph A VON Klot, Tobias L Ross, Frank M Bengel, Hans-Jürgen Wester, Hüper Katja, Hans Christiansen, Thorsten Derlin
AIM: To evaluate (68)Ga-PSMA ligand positron-emission tomography-computed tomography (PET/CT)-based radiotherapy for lymph node metastases of prostate cancer after primary therapy. PATIENTS AND METHODS: Twenty-three patients received radiotherapy for PSMA ligand-positive lymph node metastases. RESULTS: The median follow-up time was 12.4 (range=6.0-28.5) months. The median pre-treatment prostate-specific antigen (PSA) decreased from 2.75 (range=0...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28303694/lutetium-177-psma-radionuclide-therapy-for-men-with-prostate-cancer-a-review-of-the-current-literature-and-discussion-of-practical-aspects-of-therapy
#9
REVIEW
Louise Emmett, Kathy Willowson, John Violet, Jane Shin, Ashley Blanksby, Jonathan Lee
Prostate-specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high-binding affinity for the PSMA receptor have allowed high quality, highly specific PET imaging, in addition to the development of targeted radionuclide therapy for men with prostate cancer. This targeted therapy for prostate cancer has, to date, predominately used Lutetium 177 (Lu) labelled PSMA peptides...
March 2017: Journal of Medical Radiation Sciences
https://www.readbyqxmd.com/read/28283702/-68-ga-psma-pet-ct-joint-eanm-and-snmmi-procedure-guideline-for-prostate-cancer-imaging-version-1-0
#10
Wolfgang P Fendler, Matthias Eiber, Mohsen Beheshti, Jamshed Bomanji, Francesco Ceci, Steven Cho, Frederik Giesel, Uwe Haberkorn, Thomas A Hope, Klaus Kopka, Bernd J Krause, Felix M Mottaghy, Heiko Schöder, John Sunderland, Simon Wan, Hans-Jürgen Wester, Stefano Fanti, Ken Herrmann
The aim of this guideline is to provide standards for the recommendation, performance, interpretation and reporting of (68)Ga-PSMA PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of (68)Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.
March 10, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28280856/comparison-of-standard-and-delayed-imaging-to-improve-the-detection-rate-of-68-ga-psma-i-t-pet-ct-in-patients-with-biochemical-recurrence-or-prostate-specific-antigen-persistence-after-primary-therapy-for-prostate-cancer
#11
Sebastian Schmuck, Stefan Nordlohne, Christoph-A von Klot, Christoph Henkenberens, Jan M Sohns, Hans Christiansen, Hans-Jürgen Wester, Tobias L Ross, Frank M Bengel, Thorsten Derlin
PURPOSE: The aim of this study was to assess the value of dual-time point imaging in PET/CT for detection of biochemically recurrent or persistent prostate cancer, using the prostate-specific membrane antigen (PSMA) ligand [(68)Ga]PSMA I&T. METHODS: 240 patients who underwent a [(68)Ga]PSMA I&T PET/CT in the context of biochemical relapse of prostate cancer were included in this retrospective analysis. Imaging consisted of a standard whole-body PET/CT (1 h p.i.), followed by delayed (3 h p...
March 9, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28273651/comparative-preclinical-evaluation-of-68-ga-nodaga-and-68-ga-hbed-cc-conjugated-procainamide-in-melanoma-imaging
#12
György Trencsényi, Noémi Dénes, Gábor Nagy, Adrienn Kis, András Vida, Flóra Farkas, Judit P Szabó, Tünde Kovács, Ervin Berényi, Ildikó Garai, Péter Bai, János Hunyadi, István Kertész
Malignant melanoma is the most aggressive form of skin cancer. The early detection of primary melanoma tumors and metastases using non-invasive PET imaging determines the outcome of this disease. Previous studies have shown that benzamide derivatives (e.g. procainamide) conjugated with PET radionuclides specifically bind to melanin pigment of melanoma tumors. (68)Ga chelating agents can have high influence on physiological properties of (68)Ga labeled bioactive molecules, as was experienced during the application of HBED-CC on PSMA ligand...
March 1, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/28267455/gallium-68-prostate-specific-membrane-antigen-pet-imaging
#13
REVIEW
Michael S Hofman, Amir Iravani
The role of gallium-68 ((68)Ga) prostate-specific membrane antigen (PSMA) PET imaging is evolving and finding its place in the imaging armamentarium for prostate cancer (PCa). Despite the progress of conventional imaging strategies, significant limitations remain, including identification of small-volume disease and assessment of bone. Clinical studies have demonstrated that (68)Ga-PSMA is a promising tracer for detection of PCa metastases, even in patients with low prostate-specific antigen. To provide an accurate interpretation of (68)Ga-PSMA PET/computed tomography, nuclear medicine specialists and radiologists should be familiar with physiologic (68)Ga-PSMA uptake, common variants, patterns of locoregional and distant spread of PCa, and inherent pitfalls...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267453/imaging-of-prostate-cancer-using-64-cu-labeled-prostate-specific-membrane-antigen-ligand
#14
REVIEW
Aviral Singh, Harshad R Kulkarni, Richard P Baum
Prostate cancer is the most common noncutaneous cancer among men, rendering the diagnosis and staging of significant medical and public interest. One of the most interesting developments in the application of nuclear oncology has been the development of novel diagnostic agents that are able to facilitate targeted therapies using the concept of theranostics. This review summarizes the current and emerging molecular imaging techniques for the investigation of patients with prostate cancer with emphasis on the potential of (64)Cu-PSMA PET/CT in staging, restaging, and the application of theranostics...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28242977/rare-sites-of-metastases-in-prostate-cancer-detected-on-ga-68-psma-pet-ct-scan-a-case-series
#15
Sugandha Dureja, Parul Thakral, Vineet Pant, Ishita Sen
Ga-68 labeled prostate-specific membrane antigen (PSMA) whole body PET/CT scan is a novel upcoming modality for the evaluation of prostate cancer. We present three cases of prostate cancer showing rare sites of metastases like brain, penis, and liver detected on Ga-68 PSMA PET/CT scan thus emphasizing its role in lesion detection and staging.
January 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28242976/specificity-of-68-ga-psma-pet-ct-for-prostate-cancer-myths-and-reality
#16
EDITORIAL
Arun Sasikumar
68Ga-PSMA ligand PET/CT for imaging prostate cancer is a novel imaging technique, which is rapidly gaining popularity. Sufficient evidence has been accumulated in literature regarding the usefulness of (68)Ga-PSMA PET/CT in prostate cancer. Recently literature regarding the localization of (68)Ga-PSMA PET/CT imaging in non-prostatic malignancies is also published, thus questioning the specificity of the tracer with regards to prostate cancer. This commentary tries to address the issue of specificity of 68Ga-PSMA PET/CT and its relevance in imaging prostate cancer...
January 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28240670/a-rare-case-of-omentum-invasive-prostate-cancer-staging-with-psma-pet-ct-imaging-and-response-to-systemic-therapy
#17
Rahul Ladwa, Sonja Gustafson, Elizabeth McCaffrey, Kenneth Miles, Kenneth O'Byrne
The omentum is a rare metastatic site for prostatic adenocarcinoma. We present a case of metastatic castrate-resistant prostate cancer, with progressive omentum invasive prostate cancer identified on prostate-specific membrane antigen (PSMA) PET/CT scan. Omental biopsy revealed metastatic prostate adenocarcinoma, and cabazitaxel chemotherapy was instituted with a prostate-specific antigen biochemical response. Repeat PSMA PET/CT imaging revealed increased avidity in omental metastasis. Despite prostate-specific antigen response, PSMA PET/CT did not correlate with a therapeutic response...
February 24, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28240661/molecular-imaging-in-neuroendocrine-differentiation-of-prostate-cancer-68-ga-psma-versus-68-ga-dota-noc-pet-ct
#18
Sharjeel Usmani, Najeeb Ahmed, Fahad Marafi, Rashid Rasheed, Henney G Amanguno, Fareeda Al Kandari
We report on a 62-year-old man with metastatic prostate cancer (cT3b N1) diagnosed in 2011, treated with total androgen blockage with flutamide and goserelin acetate (Zoladex). He presented with left suprascapular swelling and low-back pain after being asymptomatic for 5 years. His prostate-specific antigen was 0.049 ng/mL. F-NaF PET-CT and Ga-PSMA scan were negative, whereas Ga-DOTA NOC scan done after 10 days showed multiple somatostatin-avid hepatic and lymph node metastasis.
February 24, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28240660/incidental-psma-uptake-in-an-undisplaced-fracture-of-a-vertebral-body
#19
Shankar Vamadevan, Ken Le, Choung Bui, Robert Mansberg
A 50-year-old man with recently diagnosed prostate cancer was referred for Ga-prostate-specific membrane antigen (PSMA) PET/CT with elevated prostate-specific antigen. PET/CT demonstrated increased PSMA uptake in an undisplaced transverse fracture of the L1 vertebral body. This case illustrates that PSMA uptake can occur in a transverse vertebral body fracture and is a benign cause of PSMA uptake.
February 24, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28240656/68-ga-psma-uptake-by-dermatofibroma-in-a-patient-with-prostate-cancer
#20
Funda Aydin, Arzu Akçal, Betül Ünal, Sema Sezgin Göksu, Firat Güngör
Prostate-specific membrane antigen (PSMA) is a typ. 2 transmembrane protein that is highly expressed in prostate cancer cells. Ga-PSMA PET/CT imaging is a modality used to determine the extent of prostate cancer. Various other neoplasias may also express PSMA, which appears as Ga-PSMA uptake in PET/CT imaging. A 71-year-old man with prostate cancer underwent Ga-PSMA PET/CT imaging for restaging after having an elevated prostate-specific antigen level. Subcutaneous lesions showing focal PSMA uptake were detected, one of which was excised...
February 24, 2017: Clinical Nuclear Medicine
keyword
keyword
110902
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"